Table 2 Outcomes of thiopurine therapy in patients with or without TPMT polymorphisms
TPMT mutated (N = 5) n (%)/ Median (IQR) | Wild genotype (N = 102) n (%)/ Median (IQR) | p value | |
|---|---|---|---|
Hemoglobin (g/dL) at the end of follow up | 10.8 (3.7) | 11.05 (3.4) | 0.983 |
Total leucocyte count (× 106/L) at the end of follow up | 6340 (4200) | 5700 (3575) | 0.949 |
Platelet count (× 106/L) at end of follow up | 312,000 (161,000) | 254,000 (132,500) | 0.983 |
Duration of thiopurine use (months) | 12 (14.9) | 8 (15.25) | 0.348 |
Max tolerated azathioprine equivalent dose (mg/d) | 75 (50) | 100 (25) | 0.448 |
Leukopenia | 1 (20%) | 25 (24.5%) | 1.000 |
Idiosyncratic reaction | 1 (20%) | 6 (5.9%) | 0.292 |
Treatment interruption | 1 (20%) | 29 (28.4%) | 0.532 |